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Abstract
Altered patterns of DNA methylation are key features of cancer. Nasopharyn-
geal carcinoma (NPC) has the highest incidence in Southern China. Aberrant
methylation at the promoter region of tumor suppressors is frequently reported
in NPC; however, genome-wide methylation changes have not been compre-
hensively investigated. Therefore, we systematically analyzed methylome data in
25 primary NPC tumors and nontumor counterparts using a high-throughput
approach with the Illumina HumanMethylation450 BeadChip. Comparatively,
we examined the methylome data of 11 types of solid tumors collected by The
Cancer Genome Atlas (TCGA). In NPC, the hypermethylation pattern was
more dominant than hypomethylation and the majority of de novo methylated
loci were within or close to CpG islands in tumors. The comparative methylo-
me analysis reveals hypermethylation at chromosome 6p21.3 frequently
occurred in NPC (false discovery rate; FDR=1.33 9 109), but was less obvious
in other types of solid tumors except for prostate and Epstein–Barr virus
(EBV)-positive gastric cancer (FDR<103). Bisulfite pyrosequencing results fur-
ther confirmed the aberrant methylation at 6p in an additional patient cohort.
Evident enrichment of the repressive mark H3K27me3 and active mark
H3K4me3 derived from human embryonic stem cells were found at these
regions, indicating both DNA methylation and histone modification function
together, leading to epigenetic deregulation in NPC. Our study highlights the
importance of epigenetic deregulation in NPC. Polycomb Complex 2 (PRC2),
responsible for H3K27 trimethylation, is a promising therapeutic target. A key
genomic region on 6p with aberrant methylation was identified. This region
contains several important genes having potential use as biomarkers for NPC
detection.
Introduction
It is well-known that altered patterns of DNA methylation
are key features of cancer. In particular, the cancer epige-
nome is characterized by global DNA hypomethylation
and CpG island (CGI) promoter hypermethylation. Addi-
tionally, previous studies suggested that the methylation
changes occurred at the CGI shores, regions close to CGI
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with comparatively lower CpG contents, and were impor-
tant in cancers [1, 2]. It is known that the methylation
alterations participate in the earliest stage of tumorigen-
esis [3, 4]. Therefore, systematic investigation of methyla-
tion changes in multiple types of cancers is necessary to
further understand the role of altered methylation pat-
terns in cancer initiation and development. Such compar-
ative study can identify the commonly deregulated
epigenetic machinery and discover the specific epigenetic
mechanisms contributing to certain types of cancer. The
Cancer Genome Atlas (TCGA) networks have carried out
methylome studies in multiple types of cancers, and thus,
provide a valuable data source for integrative methylation
analysis across different types of cancers.
Nasopharyngeal carcinoma (NPC) is an Epstein–Barr
virus (EBV)-associated epithelial malignancy that is the
most prevalent in southern Chinese, but is relatively rare
among Caucasians [5]. In Hong Kong, the incidence of
NPC is as high as 20–30 per 100,000 in men and 10–20
per 100,000 in women [6]. Since EBV infection is ubiqui-
tous in B lymphocytes, but is rare in epithelial cells [7], it
is generally believed that other environmental and genetic
factors are important determinants for NPC risk. Genetic
variants at human leukocyte antigen (HLA) genes, located
at the major histocompatibility complex (MHC) region
on chromosome 6p21.3, showed the strongest association
with NPC [8, 9], indicating the importance of HLA
region in NPC, although it remains unclear whether these
genetic variants are disease causal or not.
Aberrant methylation is the most frequent event for
gene silencing in NPC. For example, we and others have
reported frequent promoter hypermethylation at RASSF1,
CDKN2A, DAPK, MIPOL1, WIF1, UCHL1, THY1, and
PCDH10 in NPC [10–16]. Recent reviews include more
genes silenced by promoter hypermethylation in NPC
[17, 18]. Furthermore, we have recently shown that aber-
rant methylation at the promoter region of four tumor
suppressors provide a useful biomarker panel to detect
NPC using noninvasive plasma [12].
In this study, we systematically examined the methylo-
me data in NPC and matched nontumor adjacent
tissues. Comparison of methylome data across solid
tumors collected in TCGA studies, we found the
de novo methylated loci in cancers often had H3K4me3
and H3K27me3 marks derived from human embryonic
stem (ES) cells, suggesting a common epigenetic deregula-
tion involves both DNA methylation and histone modifi-
cation in NPC and other cancers. Furthermore, we
identified a key genomic region at chromosome 6p21.3
frequently hypermethylated in NPC. Chromosome 6p21.3
is within MHC region where HLA resides. Several genes
associated with de novo methylation from this region have
excellent prospects for clinical application.
Materials and Methods
Clinical samples
All specimens were collected by the Area of Excellence
(AoE) Hong Kong NPC Tissue Bank from Queen Mary,
Queen Elizabeth, and Pamela Youde Nethersole Eastern
Hospitals. The fresh-frozen tumor biopsies were hematox-
ylin and eosin (H&E) stained and subsequently reviewed
to determine the tumor content. DNA extraction was per-
formed using AllPrep DNA/RNA Micro Kit (Qiagen,
Valencia, CA). The quality and quantity of the DNA sam-
ples was measured by NanoDrop (Thermo Scientific,
Waltham, MA) and Qubit (Life Technologies, New York).
In total, 25 NPC tumors were included in the discovery
set and 35 NPC tumors in the validation set. The clinical
parameters of the NPC patients in the discovery and vali-
dation sets are listed in Table S1. The power analysis
showed we achieved about 80% of the power to detect
the genes aberrantly methylated in 40% of the patients in
the discovery set assuming a significance level of
5 9 105 (Fig. S1). With 35 NPC patients in the valida-
tion cohort there was about 90% of the power to validate
the candidate loci methylated in at least 40% of the
patients.
DNA methylation profiling using Infinium
Human 450k BeadArrays and data analysis
About 500 ng genomic DNA was bisulfite converted using
EZ-96 DNA MethylationTM Kit (Zymo Research, Irvine,
CA) following the manufacturer’s instructions. Illumina
Infinium Assay analysis was performed by the Centre for
Genomic Sciences at the University of Hong Kong follow-
ing Illumina’s protocol. The raw data including signal
intensities for methylated (M) and unmethylated (U)
sequences were imported into Illumina GenomeStudio
Methylation Module (Illumina, San Diego, CA). The
bisulfite conversion efficiency and overall experimental
efficiency were evaluated by the internal controls in
GenomeStudio. The background signals were subtracted
using average signal intensities of negative controls, then
the signal intensities were normalized across the samples
and converted to b value b = M/(M + U + 100) in
GenomeStudio following the manufacturer’s manual. Sub-
sequently, b values were imported into the R environ-
ment, where the following problematic probes were
removed from the analysis: (1) the cross-reactive probes
mapping to multiple locations on the genome and (2) the
probes with low signals (detection P value > 0.01) in over
90% of the samples. Given two types of probes designed
on the 450 k array display differing b value distributions,
adjustment for probe design bias was applied using a
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beta-mixture quantile normalization method (BMIQ)
[19]. The corrected b values were transformed to M-val-
ues M = log2 (b/(1  b)). Linear Models for Microarray
Data (LIMMA) analysis [20] was used to detect the CpG
sites differentially methylated between tumor and normal
tissues. The significance level of multiple testing was
adjusted using false discovery rate (FDR). The CpG sites
with FDR < 0.001 in LIMMA analysis were defined as the
loci differentially methylated in tumors. In each pair, the
CpG sites were identified as hyper- or hypo-methylated
loci, if the differential methylation between tumor and
normal tissue was greater than 0.2 (|Db| > 0.2). The un-
methylated loci in normal tissues (average bnormal < 0.3)
and peripheral blood mononuclear cells (PBMCs) (aver-
age bpbmc < 0.3), but becoming methylated in at least
40% of the tumor pairs (Db > 0.2), were identified as the
de novo methylated loci. The methylome data for PBMCs
were obtained from 100 healthy females collected by the
Marmal-aid database [21].
Meta-analysis of methylome data in eleven
types of solid tumors
The normalized methylome data on HumanMethyla-
tion450 BeadArray from eleven types of solid tumors,
including prostate, breast, pancreatic, kidney, thyroid, liver,
rectal, colon, head and neck, gastric, and lung cancers, were
obtained from Marmal-aid database [21]. Only the samples
collected in TCGA studies were used in the study. LIMMA
analysis for group comparison was used to identify the dif-
ferentially methylated loci in each type of cancer, except
gastric cancer, since only two normal gastric samples were
available for the analysis. The number of tumor and normal
tissues from each type of cancer is shown in Table S2. The
CpG sites with FDR < 0.001 in LIMMA analysis were
defined as the loci differentially methylated in tumors. The
loci unmethylated in normal tissues (average bnormal < 0.3)
and PBMCs (average bpbmc < 0.3), but methylated in at
least 40% of the tumors (btumor > 0.2) were identified as
the de novo methylated loci. All data analysis was per-
formed using the high-performance computing facility
(HPCF) provided by the Centre of Genomic Sciences at the
University of Hong Kong.
DAVID functional analysis of the aberrantly
methylated loci
The annotation of the de novo methylated loci was
obtained from Illumina BeadStudio. Only the loci within
or close to CGI were included in the analysis. The func-
tions of the genes relevant to those loci were analyzed
using the DAVID bioinformatics resources [22]. The list
of genes represented as RefSeq ID on HumanMethyla-
tion450 BeadChip was used as the background list to esti-
mate the fold of the enrichment.
Enrichment analysis of histone modification
marks
The H3K4me3 and H3K27me3 histone modification
peaks, as well as EZH2 and SUZ12 targets derived from
human ES cells, were downloaded from the UCSC gen-
ome browser [23]. Fisher’s exact test was used to evaluate
the enrichment of each mark in the aberrantly methylated
loci in each type of solid tumors.
Identification of region-specific differential
methylation in solid tumors
We developed an algorithm to detect the aberrant methyl-
ation within the large genomic regions including multiple
CpG sites significantly hypermethylated in tumors. The
method is based on the assumption that adjacent CpG
sites within 50 bp have a similar methylation level [24],
therefore, the adjacent CpG sites with FDR < 0.05 within
50 bp were merged together as a region, then the FDR of
a region was estimated as a multiplicative FDR calculated
from FDRs of all the CpG sites within the region. Since
the array-based method has design bias toward the
regions with high density of the genes, we corrected the
FDR of a region by considering the total number of CpG
sites designed in the assay (Supplementary Methods). The
analysis was performed for each type of tumor. To com-
pare the location of the regions aberrantly methylated
across tumor types, only the top 500 regions ranking on
the significant level were selected for the analysis.
Gene expression data analysis
The expression data set (GSE12452) was downloaded
from GEO database including 10 normal NP tissues and
31 laser-captured and microdissected NPC tissues. The
raw data were processed using R package affy and nor-
malized using the RMA method [25].
Bisulfite pyrosequencing
To validate the aberrantly methylated loci, we performed
bisulfite pyrosequencing. About 150 ng DNA in the dis-
covery and validation sets was bisulfite converted using
EZ DNA Methylation-LightningTM Kit (Zymo Research).
The completeness of bisulfite conversion was evaluated
using Calponin PCR [26]. The bisulfite-converted DNA
was amplified using biotin-labeled PCR primers. The cus-
tom-designed PyroMark assay IDs (Qiagen) and PCR
conditions for the selected loci are listed in Table S3.
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Bisulfite-converted CpGenome universal methylated DNA
and unmethylated DNA (Millipore, Billerica, MA) were
used as methylated and unmethylated controls. Bisulfite
pyrosequencing was performed by the Centre of Genom-
ics Sciences in the University of Hong Kong using
PSQ96MA (Biotage, Charlotte, NC) as previously
described [27].
Data access
The NPC methylome data are available in NCBI GEO
database with accession ID GSE62336.
Results
Identification of aberrant methylation in
solid tumors
Using the Illumina Infinium Assay on HumanMethyla-
tion450 BeadChip, we obtained methylation profiles of
primary tumors and adjacent nontumor tissues from 25
NPC patients. The methylome data of prostate, breast,
pancreatic, kidney, thyroid, liver, rectal, colon, lung, head
and neck, and gastric cancers were generated in TCGA
projects and obtained from Marmalaid database as
detailed in Methods. LIMMA analysis was applied to
identify the differentially methylated loci. We found the
percentage of the hypermethylated loci out of total num-
ber of differentially methylated CpG sites with
FDR < 0.001 in LIMMA analysis was variable across can-
cer types, ranging from 24% to 91% (Fig. 1A). Hyperme-
thylation was extremely frequent in NPC. Of 61825 CpG
sites differentially methylated in NPC, 52967 (91%) of the
CpG sites were hypermethylated, while only 5065 (9%) of
CpG sites became significantly hypomethylated. In con-
trast, liver cancer had reduced methylation in 76% of
CpG sites that lost methylation and only 24% of CpG
sites had increased methylation levels in tumors.
Tumor tissues were often infiltrated with lymphocytes,
therefore, in each cancer type we excluded the CpG sites
methylated in PBMCs (b > 0.3). Meanwhile, the CpG
sites methylated in normal adjacent tissues (b > 0.3) or
methylated in less than 40% of the tumors were also
removed from the analysis. In NPC, 5908 de novo
methylated autosomal CpG sites corresponding to 2069
unique genes remained and 90.4% of these loci were
within or close to CGI (CGI shore) (Fig. 1B), which is
much higher than the average level (72.3%) across 11
types of solid tumors (Fig. S2). Previously, we found the
promoter regions of RASSF1 and WIF1 were methylated
in over 60% of the NPC patients [12]. Consistently,
multiple CpG sites from promoter CGI of these two
genes were identified as significant hits in the current
study.
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Figure 1. Aberrant methylation in NPC and other types of solid tumors. (A) Percentage of hypermethylated and hypomethylated CpG sites
identified by LIMMA analysis with FDR < 0.001 in NPC and other types of solid tumors. hypo: hypomethylated CpG sites, hyper: hypermethylated
CpG sites. (B) Categories of the genomic locations of de novo methylated CpG sites in NPC. Island: CpG island, N_Shelf: north shelf region of
CGI, N_shore: north shore region of CGI, S_Shelf: south shelf region of CGI, N_Shelf: north shelf region of CGI. (C) Verification of the aberrant
methylation of six selected loci identified in NPC by bisulfite pyrosequencing. 100% methylation control; 0% no methylation control; N: normal
adjacent tissues, T: NPC tumor tissues. *Methylation level in tumor is significantly higher than matched nontumor tissue examined by Mann–
Whitney U-test with P < 0.05. NPC, nasopharyngeal carcinoma; FDR, false discovery rate; CGI, CpG island.
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We selected six de novo methylated loci close to the
genes of interest and examined the methylation level in
the tumors from the discovery set by an independent
method, bisulfite pyrosequencing. All six loci showed
increased methylation in the tumors compared to the
nontumor tissues, indicating a high accuracy for identify-
ing aberrant methylation in our study (Figs. 1C and S3).
Significant enrichment of bivalent marks at
de novo methylated loci in NPC and other
solid tumors
To identify the molecular function of the genes relevant
to the de novo methylated loci within CGIs or CGI shores
in NPC, we performed the functional enrichment analysis
using DAVID bioinformatics resources. The calcium sig-
naling pathway, wnt signaling pathway, focal adhesion,
phosphatidylinositol signaling system, regulation of actin
cytoskeleton, mitogen-activated protein kinase (MAPK)
signaling pathway, TGF-beta signaling pathway, gap junc-
tion, and hedgehog signaling pathway are often deregulat-
ed through aberrant methylation in NPC (adjusted
P < 0.2) (Table S4). Notably, these aberrantly methylated
genes frequently included HOX genes
(FDR = 4.1 9 1026) or other homeobox genes
(FDR = 8.1 9 1032). The homeobox genes often func-
tion as transcription factors; we observed a dramatic
enrichment of transcription factor activity in the analysis
(FDR = 4.4 9 1028).
DNA methylation and histone modification are depen-
dent on one another in regulating gene expression. In
normal tissues, a number of genes have the active chro-
matin mark H3K4me3 and repressive chromatin mark
H3K27me3, the so called bivalent marks. These genes are
often strong targets of DNA methylation in cancers. HOX
clusters often display both bivalent marks in pluripotent
ES cells, thus, playing an important role in development
and differentiation. Given a subset of HOX genes was
found to be aberrantly methylated in NPC and there is
crosstalk between DNA methylation and histone modifi-
cations, it is likely that the aberrantly methylated genes in
NPC are often the targets of bivalent marks. Consistent
with this hypothesis, there is noticeable enrichment of
H3K4me3 and H3K27me3 marks derived from hESCs in
the de novo methylated loci in NPC and there was obvi-
ous overlap between the loci with H3K4me3 and
H3K27me3 marks (Fig. 2A and B). Significant enrichment
of bivalent marks at the aberrantly methylated loci is not
only observed in NPC, but also noted in all other types
of cancers examined in this study, indicating the common
non-cancer NPC
Non-cancer (n = 10) NPC (n = 31)
Lo
g2
 (M
ed
ia
n 
ex
pr
es
si
on
)
1389 3516 585
H3K4me3 
(83%)
H3K27me3 
(69%)
A B
C D EZH2 SUZ12
P = 2.39x10–2
P = 1.51x10–5 P = 2x10–5
P = 1.45x10–2
EED RBBP7
0 50 100 150 200
EZH2 targets
SUZ12 targets
H3k27me3
H3k4me3
Fold enrichment
6.
00
6.
10
6.
05
6.
15
6.
20
6.
25
6.
30
6.
5
Non-cancer NPC
6.
5
10
.0
10
.5
11
.0
11
.5
7.
0
7.
5
8.
0
lo
g2
 (E
xp
re
ss
io
n)
5.
6
6.
0
6.
4
7.
5
8.
5
9.
5
lo
g2
 (E
xp
re
ss
io
n)
lo
g2
 (E
xp
re
ss
io
n)
lo
g2
 (E
xp
re
ss
io
n)
Non-cancer NPC
Non-cancer NPC Non-cancer NPC
Figure 2. Enrichment of bivalent marks at the de novo methylated loci and overexpression of polycomb complex 2 genes in NPC. (A) The de
novo methylated loci were more likely to be EZH2 and SUZ12 targets, and often had active H3K4 trimethylation marks and repressive H3K27
trimethylation marks derived from hESCs. (B) Significant overlap between the de novo methylated loci with H3K27me3 and H3K4me3. (C) Genes
with bivalent marks and associated with de novo methylated loci were downregulated in NPC. Top: Unsupervised hierarchical clustering using
expression data of the selected genes with bivalent marks and aberrantly methylated in NPC. The expression profiles of these genes can separate
the majority of the normal controls from NPC tissues; Bottom: Median expression of bivalent genes in normal controls and NPC tissues. (D)
Overexpression of EZH2, SUZ12, EED, and RBBP7 in NPC. All the expression data were obtained from GEO data set GSE12452. NPC,
nasopharyngeal carcinoma.
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epigenetic deregulation involved in cancer development
(Fig. S4). We examined the expression level of the genes
associated with the aberrantly methylated loci with biva-
lent marks using the public expression data set from
laser-captured microdissected NPC samples (GSE12452).
Expression of these genes can separate the majority of the
normal tissues from NPC tumor tissues using the unsu-
pervised hierarchical clustering method, as shown in Fig-
ure 2C. There was significant downregulation of this set
of genes in NPC compared to normal adjacent tissues
(LIMMA Mean-rank Gene Set Test one-sided
P = 1.8 9 1029), presumably through epigenetic regula-
tion.
DNA methylation and H3K27me3 often function
together in gene silencing [28]. Polycomb complex 2
(PRC2) is mainly responsible for H3K27me3 [29]. The
core human PRC2 complex comprises four components:
EZH1/2, EED, SUZ12, and RBBP7/4 [30]. Consistent with
enrichment of H3K27me3 marks in aberrant methylation,
we also found the enrichment of PRC2 major players
EZH2 and SUZ12 targets at these loci. Interestingly,
EZH2, EED, SUZ12, and RBBP7 were overexpressed at
the mRNA level in NPC (Fig. 2D). These de novo methy-
lated loci may be the potential PRC2 targets in NPC.
Frequent occurrence of aberrant
methylation at 6p in NPC
Aberrant methylation often occurs at specific regions and
there is a CGI methylator phenotype in cancers [31]. To
determine whether there is any specific genomic region
with higher hypermethylation frequencies in tumors, we
merged the individual adjacent CpG sites into small
regions as described in the Methods. Figure 3A shows the
significant level of the regions with multiple hypermethy-
lated loci across 22 chromosomes in NPC. Of the top 500
regions hypermethylated in NPC (FDR < 106), 76
regions (15.2%) localized to chromosome 6p (Fig. 3A
and B). Table S5 lists 256 important regions selected from
the top 500 regions, which were de novo methylated in
NPC (average bnormal < 0.3 and average bpbmc < 0.3). The
genes with de novo methylation on 6p in NPC include
B3GATL4 (6p21.3), HLA-L/HCG20 (6p21.3), PRRT1
(6p21.32), TNXB (6p21.3), FLOT1 (6p21.3), TRIM31
(6p21.3), LY6G5C (6p21.33), KIAA1949/PPP1R18
(6p21.3), GNL1 (6p21.3), IER3 (6p21.3), PXT1 (6p21.31),
NKAPL (6p22.1), HIST1H4F (6p22.1), and SERPINB6
(6p25) (Fig. 4A). Microarray data (GEO accession ID:
GSE12452) showed reduction in expression at B3GALT4,
TNXB, TRIM31, LY6G5C, GNL1, IER3, NKAPL, and SER-
PINB6 in NPC (P < 0.05, Fig. 4B), presumably through
epigenetic regulation. Again, these genes often contain
H3K27me3 and H3K4me3 marks derived from hESCs
(Table S5), indicating histone modification plays a role in
gene silencing in this region as well.
The genes associated with the top 500 hypermethylated
regions were frequently located at 6p21.3 in NPC
(FDR = 1.33 9 109) (Fig. 3A and B). The permutation
test showed it was unlikely this observed peak occurred
by chance or was due to any array design bias (Fig. S5).
Similarly, the analysis revealed there was a dramatic
increase in methylation level at 6p21.3 in EBV-positive
gastric tumors (n = 19) compared to EBV-negative
tumors (n = 151) (FDR = 1.98 9 105, Fig. 3C). We did
not observe the ethnic difference of Asian versus Cauca-
sian populations in the EBV-positive and EBV-negative
gastric cancer patients (EBV-positive N = 19, Asian
31.6%, Caucasian 68.4%; EBV-negative N = 159, Asian
20.5%, Caucasian 64.2%, chi-square test P = 0.68). The
especially frequent aberrant methylation at this region
may be relevant to EBV infection, but more studies are
required to further investigate this interesting finding.
Although in other types of solid tumors, we also observed
aberrant methylation in a few small regions at 6p hyper-
methylated in tumors, however, only prostate cancer also
had statistically significant enrichment of the genes hyper-
methylated at 6p21.3 (Figs. 3D–F and S6).
We further investigated the methylation level of three
selected loci from 6p21.3 in an independent patient
cohort using bisulfite pyrosequencing. Figure 5 shows
dramatic elevation of methylation at these de novo
methylated loci in NPC tumors compared to the nontu-
mor adjacent tissues.
Discussion
In this study, we investigated genome-wide methylation
changes in NPC tissues compared to their normal coun-
terparts using a high-throughput approach, and per-
formed meta-analysis of methylome data in other types of
solid tumors generated in TCGA studies. Compared to
other types of cancers, NPC had a higher hypermethyla-
tion frequency within CGI or close to CGI and very few
CpG sites were significantly hypomethylated in NPC,
indicating hypermethylation is the most frequent event in
NPC. Our results showed hypomethylation was less fre-
quent in NPC. However, the HumanMethylation450
BeadChip does not cover the repetitive elements and the
regions with poor coverage of the genes. Therefore, meth-
ylation changes at these regions were not investigated due
to the limitation of the array design.
Hypermethylation occurred across the NPC genome,
but was more striking on chromosome 6p, especially at
chromosome 6p21.3. The MHC region, which is highly
polymorphic and has a high density of genes [32], is
located in this region. Previous GWAS studies showed
1084 ª 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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multiple loci (HLA-A, HLA-F and GABBR1) within
6p21.3 were associated with NPC [8, 9]. In this analysis,
we excluded the probes targeting the sequences containing
the common single-nucleotide polymorphisms (SNPs) or
within 10 bp away from the common SNPs. So it is unli-
kely that the hypermethylated regions identified from this
study were due to the polymorphic CpG sites. Aberrant
methylation at the genes B3GATL4 (6p21.3), TNXB
(6p21.3), TRIM31 (6p21.3), LY6G5C (6p21.33),
KIAA1949/PPP1R18 (6p21.3), and GNL1 (6p21.3) identi-
fied in NPC was also hypermethylated in EBV-positive
gastric cancers compared to EBV-negative gastric cancers
(FDR < 1.6 9 1090). Several previously reported find-
ings imply that EBV infection functions as an epigenetic
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driver for tumorigenesis: (1) EBV-encoded latent mem-
brane protein 1 (LMP1) could induce expression of DNA
methyltransferases in NPC cells and in vitro EBV
infection led to extensive DNA methylation [33, 34]; (2)
EBV-positive gastric cancer showed a distinct high
hypermethylation profile [34–36]; (3) EBV infection of
immortalized oral keratinocytes induced a hypermethyla-
tor phenotype [37]; and (4) EBV could manipulate the
polycomb group protein responsible for epigenetic repres-
sion of transcription [38]. Further investigation in
EBV-associated NPC is necessary to fully understand how
EBV interacts with the host genome to affect host genome
methylation, but is beyond the scope of the current
study.
None of the genes associated with de novo methylation
from 6p21.3 have been studied in NPC. For example,
B3GALT4 belongs to the beta-1,3-galactosyltransferase
gene family. This gene family encodes type II membrane-
bound glycoproteins. B3GALT4 is located in the centro-
meric segment of the human MHC class II region.
Although the associations between B3GALT4 and ovarian
and uterine corpus cancer, as well as melanoma have been
reported [39, 40], the function of this gene is not fully
understood in cancers. We found decreased expression of
B3GALT4 was associated with poor disease-free survival
in both ovarian and lung cancers (ovarian cancer:
HR = 0.78, 95% CI 0.67–0.89, P = 0.00043; lung cancer:
HR = 0.73, 95% CI 0.58–0.92, P = 0.0075, Fig. S7), indi-
cating the likelihood that this gene plays a role in cancer
progression.
In our previous study, we have shown a methylation
gene panel including RASSF1, WIF1, RARB2, and
DAPK1 has great potential to be used as a noninvasive
and complementary test for NPC early detection in com-
bination with the EBV DNA test [12]. Although we
increased the detection rate of early-stage NPC patients
from 51.2% (EBV DNA test alone) to 64.6% (methyla-
tion panel and EBV DNA test), still more than 30% of
early-stage NPC patients cannot be identified. In this
study, we found methylation of a locus (chr6: 30711547–
30711591) from 6p21.3 region occurred in 76.5%
(13/17) of the early-stage patients from discovery and
validation sets. Therefore, combination of our methyla-
tion gene panel and the novel aberrantly methylated loci
identified in this current study, especially those loci
located at 6p21.3, might further improve the detection
rate for early-stage patients.
After integration of cancer methylome data and hESC
ChipSeq data, we found significant overlap between
de novo methylated loci and histone modification marks
H3K4me3 and H3K27me3 across all types of cancers
examined in this study. PRC2 places H3K27 trimethyla-
tion marks and is involved in various biological processes
including differentiation, proliferation, and stem cell plas-
ticity [29]. The association between de novo methylation
and bivalent markers derived from hESCs potentially links
cancer development to the stem cell theory [31]. Corre-
sponding to methylome data, expression of EZH2 and
other PRC2 members increased in NPC and many other
types of cancers, including breast, prostate, kidney, lung,
N T
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
chr6:30228041−30228076
M
et
hy
la
tio
n
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
M
et
hy
la
tio
n
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
M
et
hy
la
tio
n
N T
chr6:30711547−30711591
N T
chr6:29760751−29760786
Figure 5. Bisulfite pyrosequencing of the selected loci from 6p21.3 in the validation set. Aberrant methylation at the selected loci from 6p21.3
was further examined by bisulfite pyrosequencing in an additional NPC patient cohort. The P value was estimated using the Mann–Whitney U-
test. *P < 0.05; ***P < 0.001; ****P < 0.0001. NPC, nasopharyngeal carcinoma.
Figure 4. Methylation and expression of the genes from chromosome 6p in NPC. (A) Methylation level measured by Illumina Infinium Assay in
normal tissues (control) and NPC tissues at the genes associated with de novo methylated regions from chromosome 6p. (B) We identified the
genes aberrantly methylated in NPC from chromosome 6p and examined the expression level of these genes in normal tissues (control) and NPC
tissues. There was downregulation of expression at genes B3GALT4, TNXB, TRIM31, LY6G5C, GNL1, IER3, NKAPL, and SERPINB6 in NPC (Mann–
Whitney U-test P < 0.05), presumably through epigenetic regulation. Genes HLA-L/HCG20, PRRT1, and HIST1HF4 were not present on the
Affymetrix Human U133Plus2 array, and thus, were excluded in this analysis. The P value was estimated by Mann–Whitney U-test. NPC,
nasopharyngeal carcinoma.
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bladder, and liver cancers [41–44], and are promising
therapeutic targets in cancer therapy. Due to the limita-
tion of material obtained from NPC biopsies, we did not
directly examine H3K4me3 and H3K27me3 status in NPC
tissues. It would be necessary to examine both marks sys-
tematically to establish the direct link between DNA
methylation and histone modifications in NPC. Further-
more, small molecule inhibitors of EZH2 catalytic activity
have been developed and tested in a variety of cancers.
However, EZH2 inhibitors have not been tested in NPC.
Further evaluation of the use of EZH2 inhibitors in NPC
treatment is warranted.
Our study highlights the importance of epigenetic
deregulation in NPC. An important genomic region on
6p with aberrant methylation was identified. This region
contains several important genes having potential use as
biomarkers for NPC detection.
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